India to Philippines: Glimepiride Export Trade Route

The India to Philippines Glimepiride corridor is one of India's established pharmaceutical export routes, with 157 shipments documented worth a combined $3.4M USD. The route is dominated by AJANTA PHARMA LIMITED, which alone accounts for roughly 23% of all export value, reflecting the consolidated nature of India's glimepiride manufacturing sector.

Across 27 active suppliers, the average shipment value stands at $21.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 70% of all shipments, consistent with glimepiride's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 16 days port-to-port. The route has recorded an annual growth rate of 15.4%, placing it at rank #9 among India's top glimepiride export destinations globally.

On the import side, key buyers of Indian glimepiride in Philippines include AJANTA PHARMA PHILIPPINES INC, BROWN AND BURK PHILIPPINES INC, I.E. MEDICA INC. and 36 others. AJANTA PHARMA PHILIPPINES INC is the single largest importer with 12 shipments valued at $795.0K USD.

India's glimepiride exports to Philippines are driven primarily by a handful of large-scale manufacturers. AJANTA PHARMA LIMITED with 12 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 27 active exporters signals a competitive but concentrated market — buyers in Philippines benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — AJANTA PHARMA LIMITED, INVENTIA HEALTHCARE LIMITED, MICRO LABS LIMITED — together account for 52% of total trade value on this route. The average shipment value of $21.7K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as asenza plus 30/2 mg tablets[12060packx3x10=361800tabs]pioglitazone and glimepiride tab]each uncoated tab cont:as per inv and asenza plus 15/2 mg tablets[12600packx3x10=378000tabs]pioglitazone and glimepiride tab]each uncoated tab cont:as per inv, suggesting that buyers in Philippines tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, AJANTA PHARMA PHILIPPINES INC is the largest importer with 12 shipments worth $795.0K USD — representing 23% of all glimepiride imports from India on this route. A total of 39 buyers are active on this corridor.